Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Works matching IS 11707690 AND DT 2011 AND VI 29 AND IP 5
Results: 16
1
2
Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives.
- Published in:
- 2011
- By:
- Publication type:
- journal article
3
Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence.
- Published in:
- 2011
- By:
- Publication type:
- journal article
4
Modelling the epidemiology of infectious diseases for decision analysis: a primer.
- Published in:
- 2011
- By:
- Publication type:
- journal article
5
Health economic and infectious disease modelling: a guide to merging streams.
- Published in:
- 2011
- By:
- Publication type:
- journal article
6
Rotavirus Vaccine RIX4414 (Rotarix™).
- Published in:
- PharmacoEconomics, 2011, v. 29, n. 5, p. 439, doi. 10.2165/11207130-000000000-00000
- By:
- Publication type:
- Article
7
The Authors' Reply.
- Published in:
- 2011
- By:
- Publication type:
- Letter
8
Is There a Role for Pharmacoeconomics in Developing Countries?
- Published in:
- 2011
- By:
- Publication type:
- Letter
9
Is There a Role for Pharmacoeconomics in Developing Countries?
- Published in:
- 2011
- By:
- Publication type:
- Letter
10
Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer.
- Published in:
- PharmacoEconomics, 2011, v. 29, n. 5, p. 415, doi. 10.2165/11588340-000000000-00000
- By:
- Publication type:
- Article
11
Erratum.
- Published in:
- 2011
- Publication type:
- Correction Notice
12
Cost Effectiveness of Budesonide/Formoterol Added to Tiotropium Bromide versus Placebo Added to Tiotropium Bromide in Patients with Chronic Obstructive Pulmonary Disease.
- Published in:
- PharmacoEconomics, 2011, v. 29, n. 5, p. 403, doi. 10.2165/11590380-000000000-00000
- By:
- Publication type:
- Article
13
Cost Effectiveness of Treatments for Inflammatory Bowel Disease.
- Published in:
- PharmacoEconomics, 2011, v. 29, n. 5, p. 387, doi. 10.2165/11584820-000000000-00000
- By:
- Publication type:
- Article
14
Modelling the Epidemiology of Infectious Diseases for Decision Analysis.
- Published in:
- PharmacoEconomics, 2011, v. 29, n. 5, p. 371, doi. 10.2165/11539960-000000000-00000
- By:
- Publication type:
- Article
15
Health Economic and Infectious Disease Modelling A Guide to Merging Streams.
- Published in:
- PharmacoEconomics, 2011, v. 29, n. 5, p. 367, doi. 10.2165/11589240-000000000-00000
- By:
- Publication type:
- Article
16
Adjuvant Trastuzumab for Breast Cancer Uncertainties in Clinical and Economic Evidence Following Early Stopping of the HERA Trial.
- Published in:
- PharmacoEconomics, 2011, v. 29, n. 5, p. 361, doi. 10.2165/11588350-000000000-00000
- By:
- Publication type:
- Article